World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
68626
World Ranking
2684
National Ranking
1501

David G. Maloney publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David G. Maloney sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 689 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David G. Maloney D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David G. Maloney sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David G. Maloney is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their research primarily focuses on the field of Medicine, with a substantial number of publications addressing Oncology, Immunology, Genetics, Pathology and Forensic Medicine, and Molecular Biology.

The scientist's work heavily centers on several main topics, including:

  • CAR-T cell therapy research
  • Biosimilars and Bioanalytical Methods
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Virus-based gene therapy research
  • Immunotherapy and Immune Responses

David G. Maloney has contributed to multiple recent papers reflecting their focus on lymphoma and immunotherapy. Notable publications include:

  • "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study," 2020, The Lancet
  • "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial," 2022, The Lancet
  • "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial," 2021, The Lancet Oncology
  • "Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity," 2020, Journal of Clinical Oncology
  • "Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade," 2020, Cancer Cell

The scientist maintains frequent collaborations with other researchers in their field. Regular coauthors include Jordan Gauthier, Mazyar Shadman, Cameron J. Turtle, Alexandre V. Hirayama, and Brian G. Till.

David G. Maloney has published extensively in a range of respected venues, with many papers appearing in:

  • Blood
  • Transplantation and Cellular Therapy
  • Journal of Clinical Oncology
  • Blood Advances
  • Regular and Young Investigator Award Abstracts

Best Publications

  • Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

    Mohamed L. Sorror;Michael B. Maris;Michael B. Maris;Rainer Storb;Rainer Storb;Frederic Baron

  • IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

    David G. Maloney;Antonio J. Grillo-López;Christine A. White;David Bodkin

  • CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

    Cameron J. Turtle;Laïla Aïcha Hanafi;Carolina Berger;Theodore A. Gooley

  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

    Jeremy S Abramson;M Lia Palomba;Leo I Gordon;Matthew A Lunning

  • Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

    Peter A. McSweeney;Peter A. McSweeney;Peter A. McSweeney;Dietger Niederwieser;Dietger Niederwieser;Dietger Niederwieser;Judith A. Shizuru;Judith A. Shizuru;Judith A. Shizuru;Brenda M. Sandmaier;Brenda M. Sandmaier;Brenda M. Sandmaier

  • Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

    Juliane Gust;Kevin A. Hay;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li

  • Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

    Richard A. Miller;David G. Maloney;Roger Warnke;Ronald Levy

  • Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

    DG Maloney;TM Liles;DK Czerwinski;C Waldichuk

  • Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

    Cameron J. Turtle;Cameron J. Turtle;Laila-Aicha Hanafi;Carolina Berger;Carolina Berger;Michael Hudecek

  • Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

    Kevin A. Hay;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li;Juliane Gust

  • Chimeric antigen receptor-modified T cells derived from defined CD8 + and CD4 + subsets confer superior antitumor reactivity in vivo

    Daniel Sommermeyer;Michael Hudecek;Michael Hudecek;Paula L. Kosasih;Tea Gogishvili

  • Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

    Thomas A. Davis;Antonio J. Grillo-López;Christine A. White;Peter McLaughlin

  • IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

    D G Maloney;A J Grillo-López;D J Bodkin;C A White

  • Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

    Rebecca Gardner;David Wu;Sindhu Cherian;Min Fang

  • CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

    Brian G. Till;Brian G. Till;Michael C. Jensen;Michael C. Jensen;Jinjuan Wang;Xiaojun Qian

  • Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

    Cameron J. Turtle;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li

  • Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases

    Dietger Niederwieser;Michael Maris;Judith A. Shizuru;Effie Petersdorf

  • Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

    Marco Mielcarek;Paul J. Martin;Wendy Leisenring;Mary E. D. Flowers

  • Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT

    M.L. Sorror;M.B. Maris;M.B. Maris;R.F. Storb;R.F. Storb;F. Baron

  • Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment

    Thomas A. Davis;Christine A. White;Peter McLaughlin;Myron S. Czuczman

Frequent Co-Authors

Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Brenda M. Sandmaier
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center
Barry E. Storer
Barry E. Storer Fred Hutchinson Cancer Research Center
Oliver W. Press
Oliver W. Press University of Washington
Stanley R. Riddell
Stanley R. Riddell University of Washington
Cameron J. Turtle
Cameron J. Turtle Fred Hutchinson Cancer Research Center
Ted Gooley
Ted Gooley Fred Hutchinson Cancer Research Center
Michael A. Pulsipher
Michael A. Pulsipher University of Utah
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
William I. Bensinger
William I. Bensinger Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare but seeking alternative or accelerated paths, there are a variety of online degree programs to consider. Many professionals opt for advanced nursing degrees, such as the shortest post master's dnp program, allowing nurses to quickly reach the highest clinical degrees available. Others may prefer options that are less intensive, such as enrolling in one of the easiest dnp programs available online, which can offer greater flexibility for working adults.

Those looking to enter the healthcare field rapidly can explore fast lpn program choices. These programs get you job-ready as a Licensed Practical Nurse in less time. For individuals passionate about mental health, the fastest psychiatric nurse practitioner program can provide a streamlined route to a specialized and in-demand career.

Exploring these online pathways can be a smart way to advance your healthcare career or transition into new medical specialties—without spending years in traditional study.

Best Scientists Citing David G. Maloney

Trending Scientists

Recently Published Articles